28 April 2017

RECEIPT OF FUNDS FROM EXERCISE OF WARRANTS

Lynas Corporation (ASX:LYC, OTC:LYSDY) is pleased to announce that Lynas has received an additional $780,382.33, following an exercise of 20,536,377 Warrants that were issued on 7 September 2015, each with an exercise price of $0.038 per Warrant. As a result of the exercise of Warrants, 20,536,377 new ordinary shares will be issued today.

The funds received today will further supplement the Company’s working capital buffer in the current dynamic market environment.

Attached are the following documents concerning the exercise of Warrants:

1. Notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth)

2. Appendix 3B.

For all media enquiries please contact Renee Bertuch from Cannings Corporate Communications on +61 2 8284 9990.

Andrew Arnold
Company Secretary
28 April 2017

Issue of Shares and Notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) (Act)

We refer to the issue on 28 April 2017 of 20,536,377 ordinary shares for an exercise price of $780,382.33, following the exercise of Warrants that were issued on 7 September 2015, each of which is exercisable at $0.038 per Warrant on or before 30 September 2018.

In accordance with section 708A(6) of the Act, Lynas Corporation Limited (Lynas) confirms that:

(1) The shares were issued without disclosure to investors under Part 6D.2 of the Act.

(2) This notice is being given under section 708A(5)(e) of the Act.

(3) As at the date of this notice, Lynas has complied with:
   
   (a) the provisions of Chapter 2M as they apply to Lynas; and
   
   (b) section 674 of the Act as it applies to Lynas.

(4) As at the date of this notice, there is no information that is excluded information as defined in sections 708A(7) and 708A(8) of the Act.

Andrew Arnold
Company Secretary
Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

We (the entity) give ASX the following information.

Part 1 - All issues
You must complete the relevant sections (attach sheets if there is not enough space).

1. +Class of *securities issued or to be issued

   Ordinary Shares

2. Number of *securities issued or to be issued (if known) or maximum number which may be issued

   20,536,377

3. Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

   Ordinary Shares
4. Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

   If the additional securities do not rank equally, please state:
   - the date from which they do
   - the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
   - the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5. Issue price or consideration

   $780,382.33

6. Purpose of the issue
   (If issued as consideration for the acquisition of assets, clearly identify those assets)

   Issued on the exercise of 20,536,377 Warrants that were issued on 7 September 2015, each of which is exercisable at $0.038 per Warrant on or before 30 September 2018

6a. Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

   No

6b. The date the security holder resolution under rule 7.1A was passed

6c. Number of +securities issued without security holder approval under rule 7.1

6d. Number of +securities issued with security holder approval under rule 7.1A

---

+ See chapter 19 for defined terms.
6e Number of securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

6f Number of securities issued under an exception in rule 7.2

6g If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.

6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

6i Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

7 Dates of entering securities into uncertificated holdings or despatch of certificates

8 Number and class of all securities quoted on ASX (including the securities in section 2 if applicable)

<table>
<thead>
<tr>
<th>Number</th>
<th>Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>3,677,053,427</td>
<td>Ordinary shares</td>
</tr>
<tr>
<td>Number</td>
<td>*Class</td>
</tr>
<tr>
<td>--------</td>
<td>--------</td>
</tr>
<tr>
<td>9,443,395</td>
<td>Class 2 Employee Performance Rights exercisable for no further consideration on or before 23 September 2019</td>
</tr>
<tr>
<td>6,226,416</td>
<td>LTI Performance Rights exercisable for no further consideration on or before 23 September 2019</td>
</tr>
<tr>
<td>47,709,315</td>
<td>LTI Performance Rights exercisable for no further consideration on or before 18 September 2020</td>
</tr>
<tr>
<td>10,743,941</td>
<td>STI Performance Rights exercisable for no further consideration in the first employee trading window after 30 August 2017</td>
</tr>
<tr>
<td>23,716,708</td>
<td>LTI Performance Rights exercisable for no further consideration on or before 30 August 2021</td>
</tr>
<tr>
<td>225,000,000</td>
<td>2.75% Convertible Bonds due 30 September 2020</td>
</tr>
<tr>
<td>18,211,504</td>
<td>Warrants exercisable at $0.038 on or before 30 September 2018</td>
</tr>
<tr>
<td>348,843,836</td>
<td>Warrants exercisable at $0.05 on or before 30 September 2020</td>
</tr>
</tbody>
</table>

10. Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) | N/A

Part 2 - Bonus issue or pro rata issue

11. Is security holder approval required?

12. Is the issue renounceable or non-renounceable?
<table>
<thead>
<tr>
<th></th>
<th>Description</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>Ratio in which the *securities will be offered</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>*Class of *securities to which the offer relates</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>*Record date to determine entitlements</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Policy for deciding entitlements in relation to fractions</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Names of countries in which the entity has *security holders who will not be sent new issue documents</td>
<td>Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.</td>
</tr>
<tr>
<td>19</td>
<td>Closing date for receipt of acceptances or renunciations</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Names of any underwriters</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Amount of any underwriting fee or commission</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Names of any brokers to the issue</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Fee or commission payable to the broker to the issue</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>If the issue is contingent on *security holders’ approval, the date of the meeting</td>
<td></td>
</tr>
</tbody>
</table>
Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled.

If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders.

Date rights trading will begin (if applicable).

Date rights trading will end (if applicable).

How do security holders sell their entitlements in full through a broker?

How do security holders sell part of their entitlements through a broker and accept for the balance?

How do security holders dispose of their entitlements (except by sale through a broker)?

*Despatch date

---

**Part 3 - Quotation of securities**

You need only complete this section if you are applying for quotation of securities.

Type of securities

(tick one)

(a)  Securities described in Part 1

(b)  All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities.

+ See chapter 19 for defined terms.
Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35  If the 'securities are 'equity securities, the names of the 20 largest holders of the additional ‘securities, and the number and percentage of additional ‘securities held by those holders

36  If the ‘securities are ‘equity securities, a distribution schedule of the additional ‘securities setting out the number of holders in the categories
   1 - 1,000
   1,001 - 5,000
   5,001 - 10,000
   10,001 - 100,000
   100,001 and over

37  A copy of any trust deed for the additional ‘securities

Entities that have ticked box 34(b)

38  Number of securities for which ‘quotation is sought

39  Class of ‘securities for which quotation is sought

40  Do the ‘securities rank equally in all respects from the date of allotment with an existing ‘class of quoted ‘securities?

   If the additional securities do not rank equally, please state:
   • the date from which they do
   • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
   • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
41  Reason for request for quotation now
    Example: In the case of restricted securities, end of restriction period
    (if issued upon conversion of another security, clearly identify that other security)

<table>
<thead>
<tr>
<th>Number</th>
<th>+Class</th>
</tr>
</thead>
</table>

42  Number and +class of all +securities quoted on ASX (including the securities in clause 38)
Quotation agreement

1 Quotation of our additional securities is in ASX’s absolute discretion. ASX may quote the securities on any conditions it decides.

2 We warrant the following to ASX.
   - The issue of the securities to be quoted complies with the law and is not for an illegal purpose.
   - There is no reason why those securities should not be granted quotation.
   - An offer of the securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
     Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
   - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any securities to be quoted and that no-one has any right to return any securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the securities be quoted.
   - If we are a trust, we warrant that no person has the right to return the securities to be quoted under section 1019B of the Corporations Act at the time that we request that the securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before quotation of the securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: ___________________________ Date: 28 April 2017
Company Secretary
Print name: ANDREW ARNOLD

+ See chapter 19 for defined terms.